Company Encyclopedia
View More
name
TAILIN BIOTECH
300813.SZ
Zhejiang Tailin BioEngineering Co.,Ltd offers life science system solutions in China. The company offers cell and gene therapy solutions, including biosafety ferret isolators, sterile pig preparation solutions, aseptic filling workstation, cell preparation workstation, and robotic packaging workstations; drug development and sterile production solutions, comprising sterile packaging, highly active drug development/production, aseptic material transfer, packaging and test equipment, automated production solutions, sterility tests, and sterile connectors; microbiological detection systems; sterility testing systems; biodecontamination and infection control solutions; analytical instruments; quality control solutions, and laboratory animals/scientific research products, as well as active microbial products, and membrane materials. Its products are used in bio-pharmaceuticals, biosafety, disease control, food safety, and other industries. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd.
567.78 B
300813.SZMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking12/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.28%C
    • Profit Margin5.15%C
    • Gross Margin54.16%B
  • Growth ScoreC
    • Revenue YoY3.40%C
    • Net Profit YoY70.18%A
    • Total Assets YoY-2.91%D
    • Net Assets YoY20.52%A
  • Cash ScoreB
    • Cash Flow Margin1942.49%A
    • OCF YoY3.40%C
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreA
    • Gearing Ratio15.41%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TAILIN BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 14.7233 million yuan, an increase of 30.13%

    TAILIN BIOTECH released its third-quarter report for 2025, with operating revenue of 213 million yuan in the first three quarters, a year-on-year decrease of 12.08%. The net profit attributable to shareholders of the listed company was 14.7233 million yuan, a year-on-year increase of 30.13%. The net profit after deducting non-recurring gains and losses was 13.0487 million yuan, a year-on-year increase of 21.83%. The basic earnings per share were 0.12 yuan

    Zhitong·
    SZ
    300813
    +0.28%
    Zhitong·
    SZ
    300813
    +0.28%

    TAILIN BIOTECH: GaoDe Investment has reduced its holdings by 1.4949%

    TAILIN BIOTECH announced that GaoDe Investment will reduce its holdings by 1.2118 million shares and 600,000 shares through centralized bidding and block trading respectively from August 8, 2025, to October 15, 2025, with a reduction price range of 24.35-42.01 yuan/share and a block trading price of 27.69 yuan/share, totaling a reduction of 1.8118 million shares, accounting for 1.4949% of the company's total share capital; after the reduction, the holdings will be 5.4663 million shares, accounting for 4.51%

    Zhitong·
    SZ
    300813
    +0.28%
    Zhitong·
    SZ
    300813
    +0.28%

    TAILIN BIOTECH: Obtained 1 patent certificate

    TAILIN BIOTECH announced that its wholly-owned subsidiary, Tailin Medical Devices, recently obtained a utility model patent certificate. The patent is titled "An Automated Device for Microbial Limit Testing," with application number 2024218453749, and the authorization announcement date is September 5, 2025. The acquisition of this patent will not have a significant impact on recent production and operations, but it is beneficial for the company to further improve its intellectual property protection system, leverage its independent intellectual property advantages, establish a continuous innovation mechanism, and enhance its core competitiveness

    Zhitong·
    SZ
    300813
    +0.28%
    Zhitong·
    SZ
    300813
    +0.28%

    TAILIN BIOTECH released its performance for the first half of the year, with a net profit attributable to the parent company of 13.5429 million yuan, an increase of 105.76%

    TAILIN BIOTECH released its 2025 semi-annual report, with operating revenue of 146 million yuan, a year-on-year decrease of 6.69%. The net profit attributable to shareholders was 13.5429 million yuan, a year-on-year increase of 105.76%. The net profit after deducting non-recurring gains and losses was 13.2038 million yuan, a year-on-year increase of 116.80%. The basic earnings per share were 0.11 yuan, and it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders

    Zhitong·
    SZ
    300813
    +0.28%
    Zhitong·
    SZ
    300813
    +0.28%

    The food safety concept has rebounded sharply, and DAJY has hit the daily limit

    The food safety concept has rebounded sharply, with DAJY hitting the daily limit, followed by gains in Litong Technology, PONY, Shipu Testing, TAILIN BIOTECH, CTI, and Zhijiang Biology

    Zhitong·
    SZ
    300887
    +0.76%
    SZ
    002030
    +0.33%
    SZ
    300813
    +0.28%
    Zhitong·
    SZ
    300887
    +0.76%
    SZ
    002030
    +0.33%
    SZ
    300813
    +0.28%
    © 2025 Longbridge｜Disclaimer